DKSH Expands Korean Market with MDxK Acquisition

DKSH has announced the acquisition of Molecular Diagnostics Korea Inc. (MDxK) to enhance its scientific solutions business in South Korea. This strategic move aligns with DKSH Technology's goal of solidifying its position as a leading provider in the Asian market.

MDxK, based in Seoul and established in 2007, is recognized for its advanced solutions in molecular diagnostics and related fields. The company serves diverse clients across the life science industry, including hospitals and research institutions, with annual sales of approximately CHF 10 million.

Hanno Elbraechter of DKSH emphasizes the growing demand for scientific solutions in South Korea, with DKSH aiming to leverage synergies from this acquisition. The transaction is expected to conclude in the second quarter of 2025, pending conditions.